A Study to Evaluate Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 1)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507019-36-00

Acronym

GO42552

Enrollment

Registered

2024-08-27

Start date

2022-07-08

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma (R/R MM)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Czechia, Denmark, France, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026